Exploring immunotherapy in colorectal cancer
J Weng, S Li, Z Zhu, Q Liu, R Zhang, Y Yang… - Journal of hematology & …, 2022 - Springer
Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …
Clinical trial design in the era of precision medicine
E Fountzilas, AM Tsimberidou, HH Vo, R Kurzrock - Genome medicine, 2022 - Springer
Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …
unique molecular features that drive malignancies. Precision medicine has exploited next …
Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
Comprehensive review of targeted therapy for colorectal cancer
YH Xie, YX Chen, JY Fang - Signal transduction and targeted therapy, 2020 - nature.com
Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …
Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO …
S Fukuoka, H Hara, N Takahashi, T Kojima… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE This is a phase Ib trial of regorafenib plus nivolumab for gastric and colorectal
cancer. PATIENTS AND METHODS Enrolled patients received regorafenib plus nivolumab …
cancer. PATIENTS AND METHODS Enrolled patients received regorafenib plus nivolumab …
Molecular mechanisms of colon cancer progression and metastasis: recent insights and advancements
Colorectal cancer (CRC), the third most common type of cancer, is the second leading cause
of cancer-related mortality rates worldwide. Although modern research was able to shed …
of cancer-related mortality rates worldwide. Although modern research was able to shed …
Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient …
Importance Deficient mismatch mutation repair mechanisms may sensitize endometrial
cancers to anti–programmed death 1 (PD-1) therapies. Dostarlimab (TSR-042) is an …
cancers to anti–programmed death 1 (PD-1) therapies. Dostarlimab (TSR-042) is an …
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
Microsatellite instability: a review of what the oncologist should know
K Li, H Luo, L Huang, H Luo, X Zhu - Cancer cell international, 2020 - Springer
The patients with high microsatellite instability (MSI-H)/mismatch repair deficient (dMMR)
tumors recently have been reported that can benefit from immunotherapy, and MSI can be …
tumors recently have been reported that can benefit from immunotherapy, and MSI can be …
T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab …
PURPOSE Biomarkers that can predict response to anti–programmed cell death 1 (PD-1)
therapy across multiple tumor types include a T-cell–inflamed gene-expression profile …
therapy across multiple tumor types include a T-cell–inflamed gene-expression profile …